glp-1 gip and glucagon receptor agonists are increasingly used to treat type 2 diabetes obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal Next generation dual GLP-1/GIP, GLP-1/glucagon,
Pay in 4 interest-free payments of $6.04 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27







![Delta Sleep-Inducing Peptide [DSIP] | 62568-57-4](https://www.biosynth.com/storage/BottleImages/PD/S4/BIOSYNTH_PDS-4054.png)



















